JPH10511095A - 副甲状腺ホルモン又はその作動薬の低用量継続投与 - Google Patents
副甲状腺ホルモン又はその作動薬の低用量継続投与Info
- Publication number
- JPH10511095A JPH10511095A JP8519949A JP51994996A JPH10511095A JP H10511095 A JPH10511095 A JP H10511095A JP 8519949 A JP8519949 A JP 8519949A JP 51994996 A JP51994996 A JP 51994996A JP H10511095 A JPH10511095 A JP H10511095A
- Authority
- JP
- Japan
- Prior art keywords
- nle
- twenty
- tyr
- bpth
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000556 agonist Substances 0.000 title claims abstract description 30
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract description 44
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract description 7
- 239000000199 parathyroid hormone Substances 0.000 title abstract description 7
- 229960001319 parathyroid hormone Drugs 0.000 title abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 31
- 230000011164 ossification Effects 0.000 claims abstract description 9
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims description 23
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002071 phenylalkoxy group Chemical group 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 37
- 210000000988 bone and bone Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 230000001195 anabolic effect Effects 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 4
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 102000058004 human PTH Human genes 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- -1 2-chlorobenzyloxycarbonyl Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001593 cAMP accumulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000849 parathyroid Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 101000606274 Bos taurus Parathyroid hormone-related protein Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101150096038 PTH1R gene Proteins 0.000 description 2
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 2
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000007470 bone biopsy Methods 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical group COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000002807 parathyroid gland hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010063331 type 2 taste receptors Proteins 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒトの患者での骨形成を促進する方法であって、前記患者にPTH,PTH rP又はそれらの作動薬を10〜400単位/24時間の用量で少なくとも1カ 月間継続的に投与することを含む方法。 2.前記用量が10〜300単位/24時間である請求項1に記載の方法。 3.前記用量が10〜200単位/24時間である請求項1に記載の方法。 4.前記用量が10〜100単位/24時間である請求項1に記載の方法。 5.前記用量が100〜400単位/24時間である請求項1に記載の方法。 6.前記用量が200〜400単位/24時間である請求項1に記載の方法。 7.前記用量が300〜400単位/24時間である請求項1に記載の方法。 8.前記作動薬がhPTH1-34NH2又は[Nle8,18,Tyr34]hpTH1-3 4 NH2である請求項1に記載の方法。 9.前記作動薬がbPTH1-34NH2、[Nle8,18,Tyr34]bPTH1-34 NH2、[Nle8,18,Phe22,Tyr34]bPTH1-34NH2、[Nle8,18 ,Arg19,Tyr34]bPTH1-34NH2、[Nle8,18,Arg21,Tyr3 4 ]bPTH1-34NH2又は[Nle8,18,Arg19,21,Tyr34]bPTH1-3 4 NH2である請求項1に記載の方法。 10.前記PTH、PTHrP又はそれらの作動薬を投与するために、注入を実 施する請求項1に記載の方法。 11.前記注入を、移動可能な、又は移植可能な注入ポンプで達成する請求項1 0に記載の方法。 12.前記PTH、PTHrP又はそれらの作動薬を、徐放性処方物として投与 する請求項1に記載の方法。 13.前記徐放性処方物が、乳酸、カプロラクトン、グリコリド又はグリコール 酸から調製された重合体を含む請求項12に記載の方法。 14.骨再吸収阻害剤を前記患者に投与する段階を更に含む請求項1に記載の方 法。 15.式: [式中、A1は、Ser又はAlaであり; A7は、Leu又はPheであり; A12は、Gly、Aib、Ala又はD−Alaであり; A16は、Asn、Ser又はAlaであり; A19は、Glu、Arg、Lys、Asp、ser、Thr、Gln、Asn 又はAlaであり; A21は、Val、Met、Arg、Lys、Glu、Asp、Ser、Thr 、Gln、Asn、Leu、Ile、Nle、Ala、Phe又はp−X−Ph eであり(ここでXは、OH、CH3、NO2又はハロゲンである); A22は、Glu、Λsp、Phe、p−X−Phe(ここでXは、OH、CH3 、NO2又はハロゲンである)、Ser、Thr、Gln、Asn、Leu、I le、Nle、Val、Λla又はMetであり; A23は、Trp、1−Nal又は2−Nalであり; A34は、Phe又はp−X−Pheであり(ここでXは、OH、CH3NO2又 はハロゲンである); Wは、OH、(C1〜C12)アルコキシ、(C7〜C20)フェニルアルコキシ、 (C11〜C20)ナフチルアルコキシ又はNR3R4であるが;A12がGly、A19 がGlu、A21がVal、A22がGlnである場合、A23は1−Nal又は2− Nalでなければならず; R1、R2、R3及びR4は、それぞれ、独立に、H、(C1〜C12)アルキル、 (C7〜C10)フェニルアルキル又はCO・E(ここでEは、(C1〜C12)アル キル、(C2〜C12)アルケニル、フェニル、ナフチル又は(C7〜C20)フェニ ルアルキルである)である] を有する化合物、又は製薬上許容され得るその塩。 16.A1がAlaであり;A7がPheであり;かつA16がSerである請求項 15に記載の化合物、又は製薬上許容され得るその塩。 17.A19がGlu又はArgであり;かつA21がVal又はArgである請求 項15に記載の化合物、又は製薬上許容され得るその塩。 18.A22がp−X−Phe(ここでXはOH、CH3、NO2又はハロゲンであ る)である請求項15に記載の化合物、又は製薬上許容され得るその塩。 19.前記化合物が、[Nle8,18,Arg19,Tyr34]bPTH1-34NH2 、[Nle8,18,Arg21,Tyr34]bPTH1-34NH2又は[Nle8,18、 Arg19,24,Tyr34]bPTH1-34NH2である請求項15に記載の化合物、 又は製薬上許容され得るその塩。 20.前記化合物が、[Nle8,18,Phe22,Tyr34]bPTH1-34NH2 である請求項15に記載の化合物、又は製薬上許容され得るその塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35929394A | 1994-12-19 | 1994-12-19 | |
US08/359,293 | 1994-12-19 | ||
PCT/US1995/016554 WO1996019246A1 (en) | 1994-12-19 | 1995-12-19 | Continuous low-dose administration of parathyroid hormone or its agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10511095A true JPH10511095A (ja) | 1998-10-27 |
Family
ID=23413202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8519949A Pending JPH10511095A (ja) | 1994-12-19 | 1995-12-19 | 副甲状腺ホルモン又はその作動薬の低用量継続投与 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0800405A4 (ja) |
JP (1) | JPH10511095A (ja) |
AU (1) | AU4472896A (ja) |
CA (1) | CA2205959A1 (ja) |
WO (1) | WO1996019246A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002523375A (ja) * | 1998-08-19 | 2002-07-30 | イーライ・リリー・アンド・カンパニー | 骨の靭性、及び、剛性を増し、骨折を減少させる方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
US5955574A (en) * | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
US7410948B2 (en) | 1995-07-13 | 2008-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogs of parathyroid hormone |
US5969095A (en) * | 1995-07-13 | 1999-10-19 | Biomeasure, Inc. | Analogs of parathyroid hormone |
CA2245903A1 (en) | 1998-09-28 | 2000-03-28 | Mcgill University | Use of pex in the treatment of metabolic bone diseases |
EP1325681A1 (en) | 2001-12-11 | 2003-07-09 | Société des Produits Nestlé S.A. | Composition for promotion of bone growth and maintenance of bone health |
AU2006315132A1 (en) | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
EP2509996A1 (en) | 2009-12-07 | 2012-10-17 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2550204B1 (fr) * | 1983-08-05 | 1987-11-13 | Toyo Jozo Kk | Derives peptidiques de (nle8,nle1b, tyr34)-h-pth |
US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
JP2653255B2 (ja) * | 1990-02-13 | 1997-09-17 | 武田薬品工業株式会社 | 長期徐放型マイクロカプセル |
RU2112515C1 (ru) * | 1991-12-17 | 1998-06-10 | Проктер энд Гэмбл Фармасьютикалз, Инк. | Способ лечения остеопороза |
-
1995
- 1995-12-19 WO PCT/US1995/016554 patent/WO1996019246A1/en not_active Application Discontinuation
- 1995-12-19 EP EP95943474A patent/EP0800405A4/en not_active Withdrawn
- 1995-12-19 CA CA002205959A patent/CA2205959A1/en not_active Abandoned
- 1995-12-19 JP JP8519949A patent/JPH10511095A/ja active Pending
- 1995-12-19 AU AU44728/96A patent/AU4472896A/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002523375A (ja) * | 1998-08-19 | 2002-07-30 | イーライ・リリー・アンド・カンパニー | 骨の靭性、及び、剛性を増し、骨折を減少させる方法 |
JP2011021035A (ja) * | 1998-08-19 | 2011-02-03 | Eli Lilly & Co | 骨の靭性、及び、剛性を増し、骨折を減少させる方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2205959A1 (en) | 1996-06-27 |
EP0800405A4 (en) | 1998-11-11 |
EP0800405A1 (en) | 1997-10-15 |
WO1996019246A1 (en) | 1996-06-27 |
AU4472896A (en) | 1996-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5747456A (en) | Continuous low-dose administration of parathyroid hormone or its agonist | |
Nissenson et al. | Synthetic peptides comprising the amino-terminal sequence of a parathyroid hormone-like protein from human malignancies. Binding to parathyroid hormone receptors and activation of adenylate cyclase in bone cells and kidney. | |
JP4008825B2 (ja) | 副甲状腺ホルモンの類似体 | |
JP3963482B2 (ja) | 副甲状腺ホルモンの類似体 | |
Civitelli et al. | Parathyroid hormone-related peptide transiently increases cytosolic calcium in osteoblast-like cells: comparison with parathyroid hormone | |
AU693478B2 (en) | Treatment of obesity | |
JP4541899B2 (ja) | ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン(pth)アナログ | |
JP4837888B2 (ja) | コンホメーションが拘束された副甲状腺ホルモン(pth)類似体 | |
JPH10512280A (ja) | PTHおよびPTHrPの環式同族体 | |
JP2007518800A (ja) | Pth受容体アゴニストによる骨転移の治療 | |
NZ539218A (en) | Synthetic GHRH analogues of 29 amino acids or more | |
Rosen | The cellular and clinical parameters of anabolic therapy for osteoporosis | |
CA2221148C (en) | Muscle trophic factor | |
JPH10511095A (ja) | 副甲状腺ホルモン又はその作動薬の低用量継続投与 | |
Balasubramaniam et al. | Structure− activity studies including a ψ (CH2-NH) scan of peptide YY (PYY) active site, PYY (22− 36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine | |
Daugherty et al. | Posttranslational processing of gastrin | |
STEWART et al. | Synthetic parathyroid hormone-like protein-(1–74): Biochemical and physiological characterization | |
Schoen et al. | Growth hormone secretagogues | |
JP2002522355A (ja) | 新規な混合アミリン活性化合物 | |
Hoare et al. | Specificity and stability of a new PTH1 receptor antagonist, mouse TIP (7–39) | |
Ng et al. | Effects of exogenous growth hormone on lipid metabolism in the isolated epididymal fat pad of the growth hormone-deficient little mouse | |
Jódar-Gimeno | Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women | |
JP2001524454A (ja) | 治療方法 | |
Horiuchi et al. | The synthetic human parathyroid hormone‐related protein is inhibited by a parathyroid hormone antagonist in rats in vivo | |
Froesch | From NSILA to IGF: A look back on the major advances and breakthroughs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050428 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050620 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050801 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050920 |